These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

868 related items for PubMed ID: 30914635

  • 1. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL.
    Nat Commun; 2019 Mar 26; 10(1):1373. PubMed ID: 30914635
    [Abstract] [Full Text] [Related]

  • 2. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J.
    Breast Cancer; 2021 Jan 26; 28(1):206-215. PubMed ID: 32860163
    [Abstract] [Full Text] [Related]

  • 3. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.
    Mao P, Cohen O, Kowalski KJ, Kusiel JG, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung J, Freeman S, Rozenblatt-Rosen O, Miller VA, Piccioni F, Root DE, Regev A, Winer EP, Lin NU, Wagle N.
    Clin Cancer Res; 2020 Nov 15; 26(22):5974-5989. PubMed ID: 32723837
    [Abstract] [Full Text] [Related]

  • 4. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.
    Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.
    Clin Cancer Res; 2017 Oct 15; 23(20):6138-6150. PubMed ID: 28751448
    [Abstract] [Full Text] [Related]

  • 5. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    O'Leary B, Cutts RJ, Huang X, Hrebien S, Liu Y, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Bartlett CH, Turner NC.
    J Natl Cancer Inst; 2021 Mar 01; 113(3):309-317. PubMed ID: 32940689
    [Abstract] [Full Text] [Related]

  • 6. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.
    Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A.
    Clin Cancer Res; 2019 Nov 01; 25(21):6443-6451. PubMed ID: 31371343
    [Abstract] [Full Text] [Related]

  • 7. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S, Esposito D, Ascione CM, Messina F, Napolitano F, Servetto A, De Angelis C, Bianco R, Formisano L.
    Cancer Lett; 2024 Jul 01; 593():216968. PubMed ID: 38788968
    [Abstract] [Full Text] [Related]

  • 8. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.
    Cancer Res; 2017 May 01; 77(9):2488-2499. PubMed ID: 28249908
    [Abstract] [Full Text] [Related]

  • 9. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
    Cheng Q, Ma Z, Shi Y, Parris AB, Kong L, Yang X.
    Cells; 2021 Nov 04; 10(11):. PubMed ID: 34831231
    [Abstract] [Full Text] [Related]

  • 10. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK, Tao N, Lee KM, Huerta M, Arlt H, Mullarkey T, Troy S, Arteaga CL, Bihani T.
    Breast Cancer Res; 2019 Dec 18; 21(1):146. PubMed ID: 31852484
    [Abstract] [Full Text] [Related]

  • 11. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ.
    Am J Health Syst Pharm; 2019 Aug 01; 76(16):1183-1202. PubMed ID: 31369120
    [Abstract] [Full Text] [Related]

  • 12. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D'Cruz CM.
    Oncotarget; 2016 Aug 23; 7(34):54120-54136. PubMed ID: 27472462
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.
    Clin Cancer Res; 2015 Nov 15; 21(22):5121-5130. PubMed ID: 25991817
    [Abstract] [Full Text] [Related]

  • 14. CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison.
    Coutinho-Almeida J, Silva AS, Redondo P, Rodrigues PP, Ferreira A.
    Cancer Treat Res Commun; 2024 Nov 15; 40():100818. PubMed ID: 38761788
    [Abstract] [Full Text] [Related]

  • 15. In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
    Guffanti F, Chilà R, Bello E, Zucchetti M, Zangarini M, Ceriani L, Ferrari M, Lupi M, Jacquet-Bescond A, Burbridge MF, Pierrat MJ, Damia G.
    Neoplasia; 2017 Jan 15; 19(1):35-42. PubMed ID: 27988457
    [Abstract] [Full Text] [Related]

  • 16. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Pancholi S, Ribas R, Simigdala N, Schuster E, Nikitorowicz-Buniak J, Ressa A, Gao Q, Leal MF, Bhamra A, Thornhill A, Morisset L, Montaudon E, Sourd L, Fitzpatrick M, Altelaar M, Johnston SR, Marangoni E, Dowsett M, Martin LA.
    Oncogene; 2020 Jun 15; 39(25):4781-4797. PubMed ID: 32307447
    [Abstract] [Full Text] [Related]

  • 17. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.
    Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K, Bortolon E, Cadelina G, Gordon D, Pizzano J, Macaluso J, Soto L, Corradi J, Digianantonio K, Drulyte I, Morgan A, Quinn C, Békés M, Ferraro C, Chen X, Wang G, Dong H, Wang J, Langley DR, Houston J, Gedrich R, Taylor IC.
    Clin Cancer Res; 2024 Aug 15; 30(16):3549-3563. PubMed ID: 38819400
    [Abstract] [Full Text] [Related]

  • 18. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N, Milioli HH, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Halilovic E, Segara D, Parker A, Haupt S, Haupt Y, Tilley WD, Swarbrick A, Caldon CE, Lim E.
    Breast Cancer Res; 2020 Aug 12; 22(1):87. PubMed ID: 32787886
    [Abstract] [Full Text] [Related]

  • 19. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR, Vaillant F, Surgenor E, Policheni AN, Giner G, Capaldo BD, Chen HR, Liu HK, Dekkers JF, Sachs N, Clevers H, Fellowes A, Green T, Xu H, Fox SB, Herold MJ, Smyth GK, Gray DHD, Visvader JE, Lindeman GJ.
    Clin Cancer Res; 2020 Aug 01; 26(15):4120-4134. PubMed ID: 32245900
    [Abstract] [Full Text] [Related]

  • 20. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q, Lin X, Ye L, Xu R, Dai Y, Zhang Y, Chen Q.
    Target Oncol; 2019 Apr 01; 14(2):139-148. PubMed ID: 30941621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.